NX-1607
- Generic Name
- NX-1607
Nurix Therapeutics' BTK Degrader NX-5948 Shows Promise in B-Cell Malignancies and Autoimmune Diseases
• Nurix Therapeutics' NX-5948 demonstrates a 75.5% objective response rate in relapsed/refractory CLL/SLL patients in Phase 1 study.
• NX-5948 receives PRIME designation from EMA for CLL and Fast Track designation from FDA for Waldenstrom's Macroglobulinemia.
• Nurix plans to initiate pivotal trials for NX-5948 in CLL and expand development into autoimmune diseases in 2025.
• The company's strong financial position, with $609.6 million in cash, supports aggressive development of its pipeline.
Novartis Advances Malaria Pipeline with Long-Acting Intravenous Compound
• Novartis is developing NVP-FVP954, a long half-life intravenous compound, to combat severe malaria cases, enhancing its malaria treatment pipeline.
• The drug's formulation and pharmacokinetic properties are designed for effective treatment in patients requiring intravenous administration.
• This advancement underscores Novartis's commitment to addressing unmet needs in malaria treatment, particularly in severe and complicated cases.
Nurix Therapeutics Advances BTK Degrader NX-5948 and Reinitiates NX-2127 Trial
• Nurix Therapeutics initiated Phase 1b dose expansion of NX-5948 in CLL patients with Fast Track designation, also expanding to WM, follicular lymphoma, and marginal zone lymphoma.
• Enrollment has reinitiated for NX-2127 in a Phase 1a/b trial in oncology, utilizing a new chirally controlled drug product for dose escalation studies.
• Preclinical data on Degrader-Antibody Conjugates (DACs) were presented, highlighting a novel therapeutic class with potential for improved therapeutic index and broader applicability.
AstraZeneca Unveils Oral Small Molecule PCSK9 Inhibitor AZD0780
• AstraZeneca has disclosed AZD0780, an orally bioavailable small molecule inhibitor targeting PCSK9, potentially offering a convenient alternative to injectable therapies.
• The development of AZD0780 leverages structure-based design to optimize drug-like properties for enhanced efficacy and patient compliance.
• AZD0780 represents a significant advancement in PCSK9 inhibition, addressing the need for accessible and convenient LDL-C lowering treatments.
• This oral PCSK9 inhibitor could broaden the therapeutic landscape for hypercholesterolemia management, pending clinical trial outcomes.
Nurix Therapeutics Outlines 2024 Strategic Priorities with Focus on Cancer and Autoimmune Diseases
Nurix Therapeutics, a clinical-stage biopharmaceutical company, has outlined its 2024 strategic priorities, emphasizing the advancement of its targeted protein modulation pipeline for cancer and autoimmune diseases. The company plans to accelerate enrollment in its NX-5948 clinical trial for leukemia and lymphoma, expand its therapeutic focus to include autoimmune and inflammatory diseases, and continue its strategic collaborations with Gilead, Sanofi, and Pfizer. Nurix also reported positive Phase 1 data for its BTK degrader programs, NX-5948 and NX-2127, at the American Society of Hematology Annual Meeting.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath